Mazor Robotics, provider of surgical robots, has entered into an agreement with Cicel Science and Technology, in order to distribute its Renaissance system in China. Mazor Robotics’ renaissance system is an advanced surgical guidance system for spine procedures.
As per the agreement, Cicel will procure three Renaissance systems, which will undergo regulatory clearance from the China’s State Food and Drug Administration (SFDA). Following the receipt of SFDA clearance, Cicel will be entitled to commercialize Mazor’s Renaissance system in China for three years. Cicel, after procuring the system from Mazor, has delivered the first installment. The three Renaissance systems will be delivered following the compliance process of preset conditions.
Established in 1996, Beijing- based Cicel is a distributor of innovative medical devices in China. The products being distributed by Cicel mainly benefits domains such as endoscopy, general surgery, orthopedic and spinal surgery, and various other specialties.
The CEO of Mazor Robotics, Ori Hadomi said that local representation serves as a major criterion that promotes access to SFDA to achieve a successful market platform. Mazor considers Cicel to be its ideal partner. Cicel has achieved business with China’s chief hospitals and major medical organizations. Marking its sales and commercialization capability, Cicel possesses a complete clinical organization with excellent track record for obtaining regulatory clearance. Hence, Major Robotics is pleased to partner with Cicel, thereby establishing a strong platform in the major markets of China.
Source: http://www.mazorrobotics.com/